A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells.

The invention relates to a formulation of at least one digestive enzyme, the formulation comprising solid lipid particles, the solid lipid particles being: between 50 μm and 1200 μm in size, strictly hydrophobic, free of water, of organic solvent, of surfactant compound and of polymer, and comprising: at least one digestive enzyme, a strictly hydrophobic, non-hygroscopic waxy matrix, in which said at least one digestive enzyme: has homogeneous distribution in each solid lipid particle of the formulation, is distributed without a distribution gradient towards the interior of the waxy matrix, and represents between 0.1% and 90% of the mass of the formulation, the formulation having a melting point of between 20° C. and 65° C.

The invention relates to a hydrophobic gastro-protected formulation of at least one active principle, characterized in that it is in the form of solid particles with a size of between 5 μm and 3500 μm, the solid particles of the formulation comprising: at least one waxy excipient forming a waxy matrix; and said at least one active principle chosen from the group formed from active principles for agrifood use, active principles for veterinary use, active principles for probiotic use and active principles for pharmaceutical use;
the solid particles being strictly hydrophobic, non-hygroscopic, non-injectable, free of water, free of surfactants, free of emulsifiers, free of solvent, and free of shear-thinning polymer;
the solid particles having a melting point of between 15° C. and 60° C.;
said at least one active principle being uniformly distributed in the waxy matrix in a mass proportion of between 0.2% and 85%;
said solid particles being suitable for protecting and stabilizing said at least one active principle in a gastric medium and being dispersible in an intestinal medium.

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

The present invention refers to a delivery system for molecules, preferably drugs, said system comprising fat tissue or derivatives thereof. Moreover, the present invention refers to a fat-based delivery system, preferably loaded with molecules having antitumor activities, for use in the treatment of cancers.

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of juniperonic acid alone or in combination with other bioactive fatty acids and lipids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, sciadonic acid, conjugated linoleic acid, non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid, fish oil, olive oil, and pine nut oil.

The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet -cell function, and type 2 diabetes mellitus.

Provided are methods for modulating gut microbiota in subjects. In some embodiments, the methods include administering to a subject an effective amount of a composition that includes a first edible plant-derived nanoparticle encapsulating an effective amount of RNA. Also provided are methods for preventing and/or treating gut dysbiosis, methods for modulating bacterial growth, methods for modulating inflammatory cytokines, methods for reducing migration of bacterial from the gut to gut-associated bloodstream, and compositions for use in the presently disclosed methods, including pharmaceutical compositions.

Provided herein is an orally administrable formulation for promoting gastrointestinal health, the formulation including a plurality of plant-based polyphenol sources and/or one or more components or derivatives thereof together with one or more of a fibre source, a sweetening agent and/or a flavouring agent as well as methods of making same. Methods of using the orally administrable formulation in promoting gastrointestinal health, modulating microbial flora in a subject's gastrointestinal tract and the treatment of a gastrointestinal disease, disorder or condition are also provided.

A new type of biomaterial that can be generated from pollen, methods for its production, the various uses thereof in, for example, biological, medicinal, cosmetic, nutritional and printing applications and the materials/devices that comprise this new material are provided. Said biomaterial comprises microgels of sporoderm polymer complex microcapsules (SPC-MCs), produced by deproteinizing the pollen from eudicot plants, in particular of genus Baccharis, Helianthus or Camellia, by contacting it with an aqueous base solution at elevated temperatures for up to 10 hours to obtain porous SPC-MCs, and hydrolytically degrading the SPC-MCs by contacting it with an aqueous base solution for periods up to 60 days to obtain microgels of SPC-MCs.